Drug Trial Radar · NCT07903337
A Phase 1, Open-Label, Two-Stage, Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-1071 Under Fasted or Fed Conditions in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Elixiron Immunotherapeutics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Taipei Medical University Hospital
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1, open-label, two-stage, sequential food effect study to evaluate the safety, tolerability, and PK of EI-1071 under fasted or fed conditions in HVs. Approximately 25 evaluable participants will be enrolled in this study, including 11 participants in Stage 1 and 14 participants in Stage 2. Stage 2 study may be conducted based on the results of Stage 1 study.
Conditions
- Food Effect in Healthy Volunteers
Interventions
EI-1071Drug
EI-1071 tablet, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1 Area under the curve [AUC] from time 0 to the last quantifiable time [AUC0-t]Time frame: Day 1 to Day 4 of each single dose period
- Stage 1 AUC from time 0 to infinity [AUC0-∞], and maximum concentration [Cmax]Time frame: Day 1 to Day 4 of each single dose period
- Stage 1 Time to Cmax (Tmax)Time frame: Day 1 to Day 4 of each single dose period
- Stage 1 Half-life (t1/2)Time frame: Day 1 to Day 4 of each single dose period
- Stage 1 Apparent clearance (CL/F)Time frame: Day 1 to Day 4 of each single dose period
- Stage 1 Apparent volume of distribution (Vz/F)Time frame: Day 1 to Day 4 of each single dose period
- Stage 2 Incidence and severity of TEAEs and TESAEs,Time frame: From Day 1 to Day 21 (EOS visit)
- Stage 2 Physical examinationTime frame: Screening, Day -1, Day 21
- Stage 2 Vital signsTime frame: Screening, Day -1 to Day 21
- Stage 2 Laboratory testsTime frame: Screening, Day -1, Day 7, Day 14, Day 21
- Stage 2 12-lead ECGTime frame: Screening, Day 1, Day 14, Day 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taipei Medical University Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.